Activation and inhibition of the immune system
CA 2394880 A1 · Owner: Synovis Limited · Inventors: Foxwell, Brian; Feldmann, Marc
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Activation of the immune response by NF-.kappa.B inducers induction of an , anergic response by NF-.kappa.B inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF- .kappa.B is disclosed. Examples of NF-.kappa.B inhibitors include I.kappa.B.alpha. PSI, a nucleotide sequence encoding I.kappa.B.alpha. antisense nucleic acid encoding an NF-.kappa.B sequence such as Rel B, and anti-, NF-.kappa.B antibodies. Examples of NF-.kappa.B inducers include NIK MEKK, IKK2, TFRRF2 and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF-.kappa.B, for example adenoviral vectors.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 22, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 22, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 22, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.